Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:26 2024-09-12 am EDT			After market 03:58:09 pm
49.80 ^EUR	+2.26%		49.85	+0.10%

Aug. 16	Borse Frankfurt-News: Small caps: Recovery after setback	DP
Aug. 13	Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2024	CI

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Formycon AG

Borse Frankfurt-News: Small caps: Recovery after setback	Aug. 16	DP
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 13	CI
Formycon, Fresenius' Stelara Biosimilar for Inflammatory Diseases Secures EU Panel's Nod	Jul. 26	MT
US FDA Approves Formycon's Biosimilar to Treat Serious Retinal Diseases	Jul. 01	MT
Borse Frankfurt-News: Many winners and many losers (second-line stocks)	Jun. 18	DP
Formycon Starts Clinical Trials of Keytruda Biosimilar Candidate for Skin Cancer Therapy	Jun. 13	MT
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia	Mar. 11	MT
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	Jan. 30	MT
EU Medicines Regulator Accepts Formycon's Marketing Authorization Application for Eylea Biosimilar	Dec. 27	MT
Formycon JV Wins Canadian Approval for Retinal Diseases Treatment Ranopto	Dec. 07	MT
Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. Announces Health Canada Approves FYB201/Ranopto (Ranibizumab)	Dec. 07	CI
US FDA Accepts for Review Formycon, Fresenius' Biologics License Application for Stelara Biosimilar	Nov. 30	MT
Novartis AG : Sandoz takes its first steps on the stock exchange	23-10-04
EU Medicines Regulator Accepts Marketing Authorization Application for Formycon's Biosimilar Candidate	23-09-29	MT
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
US FDA Accepts Formycon's Biologics License Application for Eylea Biosimilar	23-08-29	MT
Formycon, Fresenius to Launch Biosimilar for Johnson & Johnson's Anti-inflammatory Drug by 2025	23-08-07	MT
Certain Shares of Formycon AG are subject to a Lock-Up Agreement Ending on 2-AUG-2023.	23-08-01	CI
Formycon Announces Submission of the Biologics License Application for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration	23-06-29	CI
Jefferies starts Formycon with 'Buy' - Target 101 euros	23-05-22	DP
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Formycon AG Provides Earnings Guidance for the Year 2023	23-04-27	CI

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Employees

239

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - Pareto Securities Healthcare Conference

More about the company